Portuguese drug giant BIAL has moved on from its fatal trial in France at the beginning of this year to celebrate the launch of its pioneering new medication to help people with Parkinson’s disease.
The drug, approved last summer by the European Commission, is designed to “reduce the period known as OFF-time” – the point characterised by profound immobility in patients.
It is being sold first in Germany and UK, but will start being made available in other European markets by next year, reports Jornal de Notícias.
BIAL has recently opened offshoots in Frankfurt and London in a bid to reinforce its strategy of internationalisation and “assure commercialisation” of its various products.
The faults behind January’s catastrophic drugs trial in France have never really been ‘proven’ (click here), though BIAL has since “definitively abandoned” the BIA 10-2474 molecule that was being tested on volunteers.
